GENERAL ORTHOPAEDICS
Biochemical markers of bone and cartilige degradation associated with progression of OA
Osteoarthritis Cartilage. 2008 Jun;16(6):660-6. Epub 2007 Nov 13.2483 patients were recruited to two parallel studies in North America (NA) and Europe (EU) to assess the effect of the structure modifying anti-OA drug, risedronate, on bone and cartilage degradation markers and radiological progression of OA. At 6 months, there was a dose-dependent induced reduction in markers of cartilage and bone degradation that was maintained until 24 months follow-up. Radiological progression of knee OA, as measure by change in joint space width (JSW), was associated with CTX-II levels throughout the study.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
